HYPERA S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.55 BRL | +5.16% |
|
+0.71% | -20.14% |
| Apr. 27 | Hypera S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 14 | Transcript : Hypera S.A., Q4 2023 Earnings Call, Mar 14, 2024 |
Presentation Operator MessageOperator (Operator)Good morning. Welcome to Hypera Pharma First Q...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Hypera (formerly Hypermarcas) is the Brazilian leader in the manufacture and marketing of pharmaceutical products. The products are sold primarily under the Addera D3, Adocyl, AdultMax, Alivium, Apracur, Atroveran, Benegrip, Bigfral, Biotonico Fontoura, Coristina, Cremer, Doril, Engov, Epocler, Lisador and Neo Quimica. The activity is organized around 3 families of products :
- OTC medicines;
- prescription medicines;
- branded generic medicines.
Sector
Pharmaceuticals
Calendar
2024-04-29
- Q1 2024 Earnings Call
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
28.55
BRL
Average target price
41.12
BRL
Spread / Average Target
+44.02%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.14% | 3.53B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- HYPE3 Stock
- News Hypera S.A.
- Transcript : Hypera S.A., Q1 2022 Earnings Call, Apr 29, 2022
